[
  {
    "ts": null,
    "headline": "Exelixis' Q2 Earnings: Will Cabometyx Sales Drive Growth?",
    "summary": "EXEL investors eye Cabometyx sales and zanzalintinib trial results ahead of Q2 earnings release on July 28.",
    "url": "https://finnhub.io/api/news?id=b075ad33a2fae1ea109694c63355af51e54ee7cb3fe863247d3bc0027704fbbd",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753282380,
      "headline": "Exelixis' Q2 Earnings: Will Cabometyx Sales Drive Growth?",
      "id": 136061042,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "INCY",
      "source": "Yahoo",
      "summary": "EXEL investors eye Cabometyx sales and zanzalintinib trial results ahead of Q2 earnings release on July 28.",
      "url": "https://finnhub.io/api/news?id=b075ad33a2fae1ea109694c63355af51e54ee7cb3fe863247d3bc0027704fbbd"
    }
  }
]